Trial Profile
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT PATIENTS WITH MILD TO MODERATE ASTHMA.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2018
Price :
$35
*
At a glance
- Drugs Lebrikizumab (Primary) ; Montelukast
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms STRETTO
- Sponsors Roche
- 01 Jan 2018 Primary endpoint has not been met. (Absolute change in pre-bronchodilator forced expiratory volume in 1 second (FEV1)) as per results published in the Respiratory Medicine
- 01 Jan 2018 Results published in the Respiratory Medicine
- 18 May 2016 Trial design presented at the 112th International Conference of the American Thoracic Society